Value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab (B) in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy (AVALUZ trial).
Manuel Codes
No relevant relationships to disclose
Luis Manso
No relevant relationships to disclose
Eva M. Ciruelos
No relevant relationships to disclose
Juan De la Haba- Rodriguez
No relevant relationships to disclose
Antonio Galan
No relevant relationships to disclose
Jose Manuel Baena
No relevant relationships to disclose
Ana Jaen
No relevant relationships to disclose
Miquel Gil
No relevant relationships to disclose
Adolfo Murias
No relevant relationships to disclose
Isabel Blancas
No relevant relationships to disclose
Encarnacion Gonzalez
No relevant relationships to disclose
Diego Perez
No relevant relationships to disclose
Juan L. Bayo
No relevant relationships to disclose
Jose Ramón Mel
No relevant relationships to disclose
Elena Garcia-Martinez
No relevant relationships to disclose
Ricardo Cubedo
No relevant relationships to disclose
Javier Salvador
No relevant relationships to disclose